BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

...during ex vivo CAR T processing and engineering. E round to fuel Enterome trial starts Enterome Bioscience S.A....
...NASDAQ:EVLO), $45 million. Targets Cbl-b - Casitas B cell lymphoma-b BioCentury Staff Nurix Therapeutics Inc. Hutchison China MediTech Ltd. Enterome Bioscience S.A. NantKwest...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...inherited retinal dystrophies, hired Rodolphe Clerval as CBO. He co-founded and served as CBO of Enterome Bioscience S.A....
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

...CMO, head of R&D and SVP at Braeburn Pharmaceuticals Inc. (Plymouth Meeting, Pa.) Microbiome company Enterome Bioscience S.A....
...Staff Agios Pharmaceuticals Inc. Arvinas Bio-Rad Laboratories Inc. Biohaven Pharmaceutical Holding Co. Ltd. CASI Pharmaceuticals Inc. Centogene AG Collegium Pharmaceutical Inc. Corium International Inc. Enterome Bioscience S.A. Petra...
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

...Mouse studies suggest immunization with bacterial peptides that mimic tumor antigens could help treat cancers Enterome Bioscience S.A....
...company has disclosed a research stage immuno-oncology program, but hasn’t released details. An abstract from Enterome Bioscience S.A....
...LSE:AZN; NYSE:AZN), Cambridge, U.K. BeyondSpring Inc. (NASDAQ:BYSI), New York, N.Y. Dana-Farber Cancer Institute, Boston, Mass. Enterome Bioscience S.A....
BioCentury | Mar 20, 2019
Company News

Enterome, Dana-Farber partner on microbiome-derived mimics of tumor antigens

...expanding on the company's own discovery of onco-mimics, or bacterial antigens that mimic tumor antigens. Enterome Bioscience S.A....
...to begin clinical trials this year to treat recurrent glioblastoma multiforme. Mary Romeo, Staff Writer Dana-Farber Cancer Institute Enterome Bioscience S.A. Institut...
BioCentury | Mar 15, 2019
Product Development

The microbiome universe in two maps

...bacterial signatures indicative of dysbiosis in inflammatory bowel disease (IBD) and irritable bowel syndrome, while Enterome Bioscience S.A....
...Companies and Institutions Mentioned 4D pharma plc (LSE:DDDD), Leeds, U.K. AOBiome Therapeutics Inc., Cambridge, Mass. Enterome Bioscience S.A....
...Mass. Vedanta Biosciences Inc., Cambridge, Mass. Winnie Pong, Senior Writer, Research & Analytics 4D Pharma plc AOBiome Therapeutics Inc. Enterome Bioscience S.A. Evelo...
BioCentury | Mar 11, 2019
Company News

Seres, AZ partner on microbiome research to treat cancer, predict response

...of it microbiome candidate VE800 in combination with Opdivo to treat advanced and metastatic cancers. Enterome Bioscience S.A....
...1; PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Elizabeth S. Eaton, Staff Writer SER-401 AstraZeneca plc Enterome Bioscience S.A. Evelo...
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

...de Cremoux. The first fund has invested in 20 microbiome-related companies, mostly in Europe, including Enterome Bioscience S.A....
BioCentury | Mar 1, 2019
Financial News

Seventure leads Axial's $25M series B

...BiomX Ltd. (Ness Ziona, Israel) announced a $32 million series B round, and in January, Enterome Bioscience S.A....
BioCentury | Feb 27, 2019
Financial News

Seventure leads Axial's $25M series B

...BiomX Ltd. (Ness Ziona, Israel) announced a $32 million series B round, and in January, Enterome Bioscience S.A....
Items per page:
1 - 10 of 59
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

...during ex vivo CAR T processing and engineering. E round to fuel Enterome trial starts Enterome Bioscience S.A....
...NASDAQ:EVLO), $45 million. Targets Cbl-b - Casitas B cell lymphoma-b BioCentury Staff Nurix Therapeutics Inc. Hutchison China MediTech Ltd. Enterome Bioscience S.A. NantKwest...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...inherited retinal dystrophies, hired Rodolphe Clerval as CBO. He co-founded and served as CBO of Enterome Bioscience S.A....
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

...CMO, head of R&D and SVP at Braeburn Pharmaceuticals Inc. (Plymouth Meeting, Pa.) Microbiome company Enterome Bioscience S.A....
...Staff Agios Pharmaceuticals Inc. Arvinas Bio-Rad Laboratories Inc. Biohaven Pharmaceutical Holding Co. Ltd. CASI Pharmaceuticals Inc. Centogene AG Collegium Pharmaceutical Inc. Corium International Inc. Enterome Bioscience S.A. Petra...
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

...Mouse studies suggest immunization with bacterial peptides that mimic tumor antigens could help treat cancers Enterome Bioscience S.A....
...company has disclosed a research stage immuno-oncology program, but hasn’t released details. An abstract from Enterome Bioscience S.A....
...LSE:AZN; NYSE:AZN), Cambridge, U.K. BeyondSpring Inc. (NASDAQ:BYSI), New York, N.Y. Dana-Farber Cancer Institute, Boston, Mass. Enterome Bioscience S.A....
BioCentury | Mar 20, 2019
Company News

Enterome, Dana-Farber partner on microbiome-derived mimics of tumor antigens

...expanding on the company's own discovery of onco-mimics, or bacterial antigens that mimic tumor antigens. Enterome Bioscience S.A....
...to begin clinical trials this year to treat recurrent glioblastoma multiforme. Mary Romeo, Staff Writer Dana-Farber Cancer Institute Enterome Bioscience S.A. Institut...
BioCentury | Mar 15, 2019
Product Development

The microbiome universe in two maps

...bacterial signatures indicative of dysbiosis in inflammatory bowel disease (IBD) and irritable bowel syndrome, while Enterome Bioscience S.A....
...Companies and Institutions Mentioned 4D pharma plc (LSE:DDDD), Leeds, U.K. AOBiome Therapeutics Inc., Cambridge, Mass. Enterome Bioscience S.A....
...Mass. Vedanta Biosciences Inc., Cambridge, Mass. Winnie Pong, Senior Writer, Research & Analytics 4D Pharma plc AOBiome Therapeutics Inc. Enterome Bioscience S.A. Evelo...
BioCentury | Mar 11, 2019
Company News

Seres, AZ partner on microbiome research to treat cancer, predict response

...of it microbiome candidate VE800 in combination with Opdivo to treat advanced and metastatic cancers. Enterome Bioscience S.A....
...1; PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Elizabeth S. Eaton, Staff Writer SER-401 AstraZeneca plc Enterome Bioscience S.A. Evelo...
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

...de Cremoux. The first fund has invested in 20 microbiome-related companies, mostly in Europe, including Enterome Bioscience S.A....
BioCentury | Mar 1, 2019
Financial News

Seventure leads Axial's $25M series B

...BiomX Ltd. (Ness Ziona, Israel) announced a $32 million series B round, and in January, Enterome Bioscience S.A....
BioCentury | Feb 27, 2019
Financial News

Seventure leads Axial's $25M series B

...BiomX Ltd. (Ness Ziona, Israel) announced a $32 million series B round, and in January, Enterome Bioscience S.A....
Items per page:
1 - 10 of 59